9 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 9 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 7 | Completed 5, Not yet recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Small Cell Carcinoma: new trials by email Literature Review of Small Cell Carcinoma trials Research Report on Small Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
| Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer Tarlatamab, Sacituzumab Govitecan - Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-04-25 | 2026-04-28 | |
| Penfluridol for Relapsed/Refractory Small Cell Cancers Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical Cancer - Small Cell Carcinoma, Small Cell Carcinoma of Lung | Phase 1 / Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 33 | 2025-10-01 | 2025-10-03 |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
| Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Apalutamide, Cetrelimab - Small Cell Neuroendocrine Carcinoma, Prostate Cancer | Phase 2 | Terminated | Rahul Aggarwal | 2 | 2022-03-16 | 2025-05-15 |
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy MDSC quantification - Melanoma, Breast Cancer | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 1000 | 2022-03-10 | 2025-05-02 | |
| The Registry of Oncology Outcomes Associated With Testing and Treatment Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P) - Adenocarcinoma, Adenocystic Carcinoma | Completed | Taproot Health | 167 | 2021-05-05 | 2024-12-18 | |
| A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. BXCL701 plus Pembrolizumab, BXCL701 monotherapy - Prostate Cancer, Neuroendocrine Tumors | Phase 1 / Phase 2 | Completed | BioXcel Therapeutics Inc | 98 | 2019-02-12 | 2026-05-15 |
| Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma Nortriptyline Hydrochloride, Paclitaxel - Small Cell Carcinoma | Phase 1 | Completed | University of Washington | 2 | 2016-11-03 | 2019-12-17 |
| Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 157 | 2016-08-15 | 2026-07-17 |
| RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) RRx-001, Cisplatin, Etoposide - Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | EpicentRx, Inc. | 139 | 2015-06-01 | 2025-03-17 |
| Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Cisplatin, Etoposide, Veliparib - Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 156 | 2012-09-28 | 2026-06-24 |
| Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer Hypofractionated Chest Radiotherapy - Lung Neoplasm, Small Cell Carcinoma | Phase 2 | Completed | AHS Cancer Control Alberta | 2 | 2009-06-01 | 2016-02-22 |
| Cone Beam CT Scanning in Lung and Bladder Cancer. Lung Neoplasm, Small Cell Carcinoma | Completed | AHS Cancer Control Alberta | 22 | 2007-05-01 | 2016-02-24 | |
| Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer Topotecan, Sorafenib - Small Cell Carcinoma, Lung Cancer | Phase 1 | Completed | HealthPartners Institute | 16 | 2007-04-01 | 2015-12-16 |
| Hypofractionated Radiotherapy for Small Cell Lung Cancer hypofractionated external beam - Lung Neoplasm, Small Cell Carcinoma | Phase 1 | Completed | AHS Cancer Control Alberta | 24 | 2007-03-01 | 2016-02-25 |
Carcinoma, Small Cell (16) · Small Cell Lung Carcinoma (9) · Lung Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Melanoma (3) · Neuroendocrine Tumors (3) · Prostatic Neoplasms (3) · Urinary Bladder Neoplasms (3) · Anus Neoplasms (2) · Breast Neoplasms (2) · Neoplasms, Unknown Primary (2) · Penile Neoplasms (2) · Pheochromocytoma (2) · Squamous Cell Carcinoma of Head and Neck (2)
Carcinoma (16) · Neoplasms by Histologic Type (16) · Neoplasms, Glandular and Epithelial (16) · Neoplasms (15) · Neoplasms by Site (15) · Lung Diseases (12) · Respiratory Tract Diseases (12) · Respiratory Tract Neoplasms (12) · Thoracic Neoplasms (12) · Bronchial Neoplasms (10) · Carcinoma, Bronchogenic (10) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Male Urogenital Diseases (7) · Neoplasms, Germ Cell and Embryonal (7)
Etoposide (3) · Carboplatin (2) · Cisplatin (2) · Paclitaxel (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Biological Therapy (1) · Drug Therapy (1) · EC regimen (1) · Gemcitabine (1) · Immunotherapy (1) · Irinotecan (1) · Molecular Diagnostic Techniques (1) · Nortriptyline (1) · PM 01183 (1)
AHS Cancer Control Alberta (3) · National Cancer Institute (NCI) (2) · BioXcel Therapeutics Inc (1) · EpicentRx, Inc. (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · HealthPartners Institute (1) · M.D. Anderson Cancer Center (1) · MacroGenics (1) · Rahul Aggarwal (1) · SystImmune Inc. (1) · Taproot Health (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · University of Washington (1)
United States (11) · Canada (4) · Italy (3) · Australia (2) · France (2) · Poland (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Bulgaria (1) · China (1) · Czechia (1) · Georgia (1) · Germany (1) · Greece (1)
Don Yee, MD (2) · Amir Hafeez, MD (1) · Anish Thomas, M.D. (1) · Aung Naing (1) · Bryan Oronsky, MD, PhD (1) · Jennifer Johnson, MD, PhD (1) · Joseph Leach, MD (1) · Junliang Cai, MD (1) · Licia Rivoltini (1) · Liudmila Schafer, M.D. (1) · Peng Wu, PhD (1) · Rahul Aggarwal, MD (1) · Raymond Bergan, MD (1) · Razelle Kurzrock, MD (1) · Robert Montgomery (1)
PMID 29149611, PMID 30523756, PMID 31231122, PMID 31533818, PMID 32188704, PMID 32303619, PMID 32534809, PMID 32860331, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33569311, PMID 33770291, PMID 34241781, PMID 34725215, PMID 35618285, PMID 35999229, PMID 37568622, PMID 40212844, PMID 41143139, PMID 42114950, PMID 42342409
P30CA015704 (1), U10CA021115 (1), U10CA180820 (1), U24CA196172 (1)